These findings are important, as they may indicate that childhood trauma exposure does not pose the same risk for a poor treatment response to ayahuasca, as it predicts in other forms of intervention.

These findings suggest that a single administration of psilocybin is safe with regard to acute psychological and physical harm in healthy participants in a controlled research setting.

Among a comprehensive set of acute experiences related to psilocybin, so-called “mystical experience” and “ego dissolution” were unique in mediating the effect of treatment condition on depressive response with high specificity. Higher reported levels of mystical experience, emotional breakthrough, and intense responses to music-listening were furthermore associated with greater antidepressant response.

Psychedelic-assisted therapy teams may benefit from including spiritual health practitioners. In order to ensure rigorous standards and quality care, further efforts to delineate the roles and necessary qualifications and training of spiritual health clinicians for psychedelic-assisted therapy are needed.

We hypothesize that at subanesthetic doses, ketamine produces a unique spectrum of altered states, ranging from psychoactive to deep ego-dissolving experiences, that are intrinsic to ketamine’s therapeutic effects.

These findings highlight the importance of the therapeutic relationship in PAT. Future research should explore therapist and participant characteristics which maximize the therapeutic alliance and evaluate its relationship to treatment outcomes.

This study aims to reconcile this knowledge gap by surveying PAT practitioners on the dimensions of their treatment that vary across the field, such as dosages and session durations. This input will help us develop a better understanding of the landscape of PAT approaches and strengthen the methods used in future psychedelic trials.

In conclusion, our synaptic protein findings suggest that PME (mushroom extract) has a more potent and prolonged effect on synaptic plasticity than PSIL (synthesized psilocybin).

"The obvious gap in the palliative care toolbox is a tool for the relief of nonphysical suffering, and psilocybin is that tool." "It's really essential that everyone in patients' rights, hospice and the palliative care movement stand up and insist that it be available sooner rather than later."

This report is from a non-medical psychedelic retreat centre documenting participant responses to a series of surveys on continuing benefits for depression and anxiety symptoms.

Alongside what are undoubtedly some real and heart-rending personal accounts, there’s reason to be skeptical about the veracity of the memories retrieved while under the influence of psychedelics.

This is the first time psilocybin has been investigated for treatment of generalised anxiety disorder, and the reduction in HAM-A scores we have observed are far greater those reported from trials on established medicines for treatment of anxiety.

FDA has granted breakthrough designation to its MM120 (lysergide d-tartrate) program for the treatment of generalized anxiety disorder (GAD)."

An interesting review has been published exploring the different technologies that are assisting psychedelic research. This review (2024) discusses the pivotal role of neuroimaging in modern psychedelic research, providing insights into the acute and longer-term therapeutic effects of these substances. Evidence from ffMRI, PET, and MEG/EEG studies informs computational models, offering a comprehensive understanding of the effects of psychedelics on human consciousness as well as supporting the advancement of psychedelic therapies.

Conclusions PAP was feasible in complex patients with preliminary antidepressant efficacy and adequate safety and tolerability. Repeated doses were associated with greater reductions in depression severity.

Our findings suggest that the long-term social-emotional benefits of MDMA are associated with whether users seek self-insight or have mixed intentions.

Path analysis using structural equation modeling showed that psychological insight, not metaphysical beliefs, uniquely predicted beneficial outcomes. Moreover, beneficial outcomes’ positive relation to ego dissolution and therapeutic intent was fully mediated by psychological insight.

Our studies provide compelling evidence for the existence of a measurable psychological state of psychedelic preparedness, which is predictive of positive acute and long-term outcomes associated with psychedelic use.

The FDA has granted the application priority review and has assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 11, 2024 to make the review determination.